(May 24, 2016)

Sponsored by
Thomson Reuters Logo


With the increasing deluge of biological data produced by today’s Life Science R&D teams, there is a growing bottleneck in having all this valuable data analysed by suitably qualified bioinformaticians. Slower turnaround of data analytics leads to a slower overall project timeline, decreased efficiency and in turn increased costs. One solution to the solution is the empowerment of bench biologists to analyse the biological impact of the data, either directly or through on demand outsourced bioinformatics support. In this symposium we discuss how Thomson Reuters is working to empower the biologist and lead the way in the rise of the “citizen bioinformatician.”

Learning Objectives:

  • Better understand how to select your biological targets
  • Define your company’s strategy to landscape targets within therapeutic areas
  • Gain insights to choose pre-clinical models
  • Integrate best practices implemented by other companies to better respond to current challenges

Who Should Attend:

  • Head of Therapy Area Research
  • Director Bioinformatics
  • Director Translational Medicine
  • Director Genomics
  • Research Scientist


Chris Willis, PhD

Manager, Discovery Solution Scientists

Thomson Reuters

Chris Willis holds an undergrad degree from the University of Delaware and a PhD in Biochemistry from the University Of Maryland School Of Medicine. As a postdoc, he worked in translational research at the Kimmel Cancer Center studying cancer signaling mechanisms. For the last four years his work at Thomson Reuters has involved knowledge and data driven approaches to scientific questions. In his current role, he manages an international team of scientists working in the discovery, translational and pre-clinical space.

Matthew Wampole, PhD

Solution Scientist, Discovery Science

Thomson Reuters

Matthew Wampole holds a Bachelor’s of Science from Elizabethtown College as well as a Masters and PhD in Chemistry with a focus on computational chemistry from Bryn Mawr College. His training continued as a postdoctoral researcher at Thomas Jefferson University for 4 years, where he worked in a multi-disciplinary team developing tumor specific imaging probes to help stratify cancer patients with KRAS mutations. After his time as a postdoc, Matt joined Thomson Reuters as a Solution Scientist for the past 2 years. In this role, he supports discussions on using knowledge and data driven methods for answering scientific questions in the discovery, pre-clinical, and translational areas of drug development.